Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

NCT00569335 Phase 2 COMPLETED

Phase II trial of combination therapy with S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer

Details

Lead sponsor	Taiho Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	52
Start date	2007-10
Completion	2010-03

Conditions

• Colorectal, Cancer

Interventions

• S-1, Irinotecan, Bevacizumab

Primary outcomes

• Safety — any time

Countries

Japan